Minorities Lack Internet Access to Cancer Research Data

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

BETHESDA, Md--Cable television, not computers, may be the best way to reach the poor with information about cancer research, Harold P. Freeman, MD, said at a meeting of the National Cancer Advisory Board (NCAB) that focused on issues of minority recruitment into clinical trials.

BETHESDA, Md--Cable television, not computers, may be the bestway to reach the poor with information about cancer research,Harold P. Freeman, MD, said at a meeting of the National CancerAdvisory Board (NCAB) that focused on issues of minority recruitmentinto clinical trials.

Dr. Freeman, director of surgery, Harlem Hospital Center, andchair of the President's Cancer Panel, said that "we continueto isolate the poor, those without the equipment to search theInternet, those without phones to call for information. The Internethas elitist demographics, no quality control, and no securityof information."

He recommended that an "800" phone number be made availableand widely published for those without computers who want to obtainthe same information that is being given out on the Internet.And for those who have no telephones, Dr. Freeman said that cabletelevision is currently much used by the poor and by minoritycultures, and thus would be a good means of disseminating cancerinformation.

He added that, for those patients with Internet access, the balanceof power between patient and physician may shift. "In thefuture, patients will come to their physicians with more knowledge."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content